Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Jan 10

PMID 30621214

Citations 7

Authors

Nicholas Pulliam

Jessica Tang

Weini Wang

Fang Fang

Riddhi Sood

Heather M OHagan

Kathy D Miller

Robert Clarke

Kenneth P Nephew

Affiliations

Soon will be listed here.

Abstract

Therapeutic targeting of estrogen receptor-α (ERα) by the anti-estrogen tamoxifen is standard of care for premenopausal breast cancer patients and remains a key component of treatment strategies for postmenopausal patients. While tamoxifen significantly increases overall survival, tamoxifen resistance remains a major limitation despite continued expression of ERα in resistant tumors. Previous reports have described increased oxidative stress in tamoxifen resistant versus sensitive breast cancer and a role for PARP1 in mediating oxidative damage repair. We hypothesized that PARP1 activity mediated tamoxifen resistance in ERα-positive breast cancer and that combining the antiestrogen tamoxifen with a PARP1 inhibitor (PARPi) would sensitize tamoxifen resistant cells to tamoxifen therapy. In tamoxifen-resistant vs. -sensitive breast cancer cells, oxidative stress and PARP1 overexpression were increased. Furthermore, differential PARylation of ERα was observed in tamoxifen-resistant versus -sensitive cells, and ERα PARylation was increased by tamoxifen treatment. Loss of ERα PARylation following treatment with a PARP inhibitor (talazoparib) augmented tamoxifen sensitivity and decreased localization of both ERα and PARP1 to ERα-target genes. Co-administration of talazoparib plus tamoxifen increased DNA damage accumulation and decreased cell survival in a dose-dependent manner. The ability of PARPi to overcome tamoxifen resistance was dependent on ERα, as lack of ERα-mediated estrogen signaling expression and showed no response to tamoxifen-PARPi treatment. These results correlate ERα PARylation with tamoxifen resistance and indicate a novel mechanism-based approach to overcome tamoxifen resistance in ER+ breast cancer.

Citing Articles

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.

Bhagwat S, Mur C, Vandekopple M, Zhao B, Shen W, Marugan C Cancer Res. 2024; 85(4):777-790.

PMID: 39652577 PMC: 11831106. DOI: 10.1158/0008-5472.CAN-24-2608.

Human PARP1 substrates and regulators of its catalytic activity: An updated overview.

Zhu T, Zheng J, Huang L, Wang Y, Yao D, Dai H Front Pharmacol. 2023; 14:1137151.

PMID: 36909172 PMC: 9995695. DOI: 10.3389/fphar.2023.1137151.

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer.

Hany D, Zoetemelk M, Bhattacharya K, Nowak-Sliwinska P, Picard D Cell Mol Life Sci. 2023; 80(3):80.

PMID: 36869202 PMC: 10032341. DOI: 10.1007/s00018-023-04730-x.

A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.

Asghari A, Wall K, Gill M, Del Vecchio N, Allahbakhsh F, Wu J Oncotarget. 2022; 13:600-613.

PMID: 35401937 PMC: 8986262. DOI: 10.18632/oncotarget.28225.

Unconventional protein post-translational modifications: the helmsmen in breast cancer.

Liu J, Wang Q, Kang Y, Xu S, Pang D Cell Biosci. 2022; 12(1):22.

PMID: 35216622 PMC: 8881842. DOI: 10.1186/s13578-022-00756-z.

References

Schiff R, Reddy P, Ahotupa M, Grim M, Hilsenbeck S, Lawrence R . Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000; 92(23):1926-34. DOI: 10.1093/jnci/92.23.1926. View

Lee Y, Kang Y, Lee S, Kim J . Role of NAD(P)H oxidase in the tamoxifen-induced generation of reactive oxygen species and apoptosis in HepG2 human hepatoblastoma cells. Cell Death Differ. 2001; 7(10):925-32. DOI: 10.1038/sj.cdd.4400717. View

Razandi M, Oh P, Pedram A, Schnitzer J, Levin E . ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol. 2002; 16(1):100-15. DOI: 10.1210/mend.16.1.0757. View

Girdler F, Brotherick I . The oestrogen receptors (ER alpha and ER beta) and their role in breast cancer: a review. Breast. 2004; 9(4):194-200. DOI: 10.1054/brst.2000.0203. View

Gutierrez M, Detre S, Johnston S, Mohsin S, Shou J, Allred D . Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005; 23(11):2469-76. DOI: 10.1200/JCO.2005.01.172. View

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

Kim M, Zhang T, Kraus W . Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. Genes Dev. 2005; 19(17):1951-67. DOI: 10.1101/gad.1331805. View

Kallio A, Zheng A, Dahllund J, Heiskanen K, Harkonen P . Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis. 2005; 10(6):1395-410. DOI: 10.1007/s10495-005-2137-z. View

10.

Dowsett M, Nicholson R, Pietras R . Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance. Breast Cancer Res Treat. 2005; 93 Suppl 1:S11-8. DOI: 10.1007/s10549-005-9037-3. View

11.

Ju B, Lunyak V, Perissi V, Garcia-Bassets I, Rose D, Glass C . A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006; 312(5781):1798-802. DOI: 10.1126/science.1127196. View

12.

Fan M, Yan P, Hartman-Frey C, Chen L, Paik H, Oyer S . Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006; 66(24):11954-66. DOI: 10.1158/0008-5472.CAN-06-1666. View

13.

Badia E, Oliva J, Balaguer P, Cavailles V . Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem. 2008; 14(28):3035-45. PMC: 2789301. DOI: 10.2174/092986707782794023. View

14.

Sakai W, Swisher E, Karlan B, Agarwal M, Higgins J, Friedman C . Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008; 451(7182):1116-20. PMC: 2577037. DOI: 10.1038/nature06633. View

15.

Trachootham D, Alexandre J, Huang P . Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov. 2009; 8(7):579-91. DOI: 10.1038/nrd2803. View

16.

Sakai W, Swisher E, Jacquemont C, Chandramohan K, Couch F, Langdon S . Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009; 69(16):6381-6. PMC: 2754824. DOI: 10.1158/0008-5472.CAN-09-1178. View

17.

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

18.

Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C . MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst. 2010; 102(10):706-21. PMC: 2873185. DOI: 10.1093/jnci/djq102. View

19.

Osborne C, Schiff R . Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2010; 62:233-47. PMC: 3656649. DOI: 10.1146/annurev-med-070909-182917. View

20.

Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C . MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2010; 30(9):1082-97. PMC: 3342929. DOI: 10.1038/onc.2010.487. View